Alkermes plc Completes Secondary Offering of 24,150,000 Ordinary Shares Held by Elan
Alkermes plc (NASDAQ: ALKS) (“Alkermes”) today announced the completion of an underwritten public offering of 24,150,000 ordinary shares held by a subsidiary of Elan Corporation, plc (“Elan”) at a price to the public of $16.50 per share, which includes 3,150,000 ordinary shares in connection with the full exercise by the underwriters of their option to purchase additional shares. Alkermes did not receive any proceeds from the offering, and its total number of ordinary shares outstanding did not change as a result of the offering. Citigroup, Jefferies & Company, Inc. and Morgan Stanley acted as joint book-running managers. Berenberg Bank and Cowen and Company, LLC acted as co-managers for the offering. The Elan subsidiary continues to own 7,750,000 ordinary shares, which are subject to transfer restrictions set forth in a shareholder’s agreement by and between Alkermes, Elan and the Elan subsidiary.
The securities described above were offered pursuant to a registration statement on Form S-1 declared effective by the Securities and Exchange Commission (“SEC”) on March 2, 2012, which is available on the SEC’s website at www.sec.gov. Copies of the prospectus and the accompanying base prospectus relating to this offering may be obtained by request to any of the following: Citigroup, Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220, 800-831-9146 or email@example.com; Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, 877-547-6340 or Prospectus_Department@Jefferies.com; or Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, 866-718-1649 or firstname.lastname@example.org.
About Alkermes plc
Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
Rebecca Peterson, +1 781 609 6378